Aflibercept, bevacizumab and ranibizumab prevent glucose-induced damage in human retinal pericytes in vitro, through a PLA2/COX-2/VEGF-A pathway (Q40856400)
Jump to navigation
Jump to search
scientific article published on 6 June 2015
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Aflibercept, bevacizumab and ranibizumab prevent glucose-induced damage in human retinal pericytes in vitro, through a PLA2/COX-2/VEGF-A pathway |
scientific article published on 6 June 2015 |
Statements
1 reference
Aflibercept, bevacizumab and ranibizumab prevent glucose-induced damage in human retinal pericytes in vitro, through a PLA2/COX-2/VEGF-A pathway (English)
1 reference
1 reference
1 reference
Giovanni Giurdanella
1 reference
Melania Olivieri
1 reference
Nunzia Caporarello
1 reference
6 June 2015
1 reference
1 reference
Identifiers
1 reference